Biblio

Filters: Author is Kato, Koji [Clear All Filters]

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A

Hashimoto S, Kato K, Kai S, Sekimoto T, Minemoto M, Ishii H, Mori T, Azuma F, Ishimaru F, Kimura T, et al. Adverse events caused by cord blood infusion in Japan during a 5-year period. Vox Sang. 2022.

Hangai M, Urayama KY, Tanaka J, Kato K, Nishiwaki S, Koh K, Noguchi M, Kato K, Yoshida N, Sato M, et al. Allogeneic stem cell transplantation for acute lymphoblastic leukemia in adolescents and young adults. Biol Blood Marrow Transplant. 2019.

Ishida H, Shimada H, Tanizawa A, Shimazu Y, Tachibana T, Doki N, Ara T, Matsuo Y, Nara M, Toubai T, et al. Allogeneic stem cell transplantation for children and adolescents/young adults with de novo blastic phase chronic myeloid leukemia in the tyrosine kinase inhibitor era. Am J Hematol. 2023.

C

Okinaka K, Inoue Y, Uchida N, Toya T, Ogawa H, Ozawa Y, Eto T, Mori T, Sugita J, Kondo T, et al. Clinical characteristics and risk factors of pneumococcal diseases in recipients of allogeneic hematopoietic stem cell transplants in the late phase: A retrospective registry study. J Infect Chemother. 2023.

Ito Y, Miyamoto T, Kamimura T, Takase K, Henzan H, Sugio Y, Kato K, Ohno Y, Eto T, Teshima T, et al. Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group. Int J Hematol. 2013.

Takashima S, Miyamoto T, Kadowaki M, Ito Y, Aoki T, Takase K, Shima T, Yoshimoto G, Kato K, Muta T, et al. Combination of bortezomib, thalidomide, and dexamethasone (VTD) as a consolidation therapy after autologous stem cell transplantation for symptomatic multiple myeloma in Japanese patients. Int J Hematol. 2014.

Kato M, Ishida H, Koh K, Inagaki J, Kato K, Goto H, Kaneko T, Cho Y, Hashii Y, Kurosawa H, et al. Comparison of chemotherapeutic agents as a myeloablative conditioning with total body irradiation for pediatric acute lymphoblastic leukemia: A study from the pediatric ALL working group of the Japan Society for Hematopoietic Cell Transplantation. Pediatr Blood Cancer. 2015.

Inamoto Y, Kimura F, Kanda J, Sugita J, Ikegame K, Nakasone H, Nannya Y, Uchida N, Fukuda T, Yoshioka K, et al. Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups. Haematologica. 2016.

Tokunaga M, Nakano N, Fuji S, Wake A, Utsunomiya A, Ito A, Eto T, Kawakita T, Mori Y, Moriuchi Y, et al. Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study. Bone Marrow Transplant. 2023.

D

Dreyling M, Fowler NH, Dickinson M, Martínez-López J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, et al. Durable Response After Tisagenlecleucel in Adults With Relapsed/Refractory Follicular Lymphoma: ELARA Trial Update. Blood. 2024.

E

Uchida M, Kato K, Ikesue H, Ichinose K, Hiraiwa H, Sakurai A, Muta T, Takenaka K, Iwasaki H, Miyamoto T, et al. Efficacy and Safety of Aprepitant in Allogeneic Hematopoietic Stem Cell Transplantation. Pharmacotherapy. 2013.

H

Ishida H, Kawahara Y, Tomizawa D, Okamoto Y, Hama A, Cho Y, Koh K, Koga Y, Yoshida N, Sato M, et al. A higher CD34 + cell dose correlates with better event-free survival after KIR-ligand mismatched cord blood transplantation for childhood acute myeloid leukemia. J Hematol Oncol. 2024;17(1):24.

I

Shimomura Y, Kitamura T, Murata M, Matsuo K, Ito Y, Ichinohe T, Hashii Y, Goto H, Kato K, Ishimaru F, et al. Impact of center volume on chronic graft versus host disease in patients with allogeneic stem cell transplantation. Transplant Cell Ther. 2024.

Uchida M, Ishida S, Mochizuki E, Ozawa N, Yonemitsu H, Ochiai H, Nakamura H, Kawashiri T, Kato K, Egashira N, et al. Improvement of Medication Guidance Sheet for Total Body Irradiation/Cyclophosphamide Followed by Allogeneic Hematopoietic Stem Cell Transplantation Based on Real Monitoring Data. Anticancer Res. 2023;43(9):4067-4075.

L

Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Damon LE, et al. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. Lancet Oncol. 2021.

M

Uchiyama T, Kawai T, Nakabayashi K, Nakazawa Y, Goto F, Okamura K, Nishimura T, Kato K, Watanabe N, Miura A, et al. Myelodysplasia after clonal hematopoiesis with APOBEC3-mediated CYBB inactivation in retroviral gene therapy for X-CGD. Mol Ther. 2023.

O

Shima T, Miyamoto T, Kikushige Y, Yuda J, Tochigi T, Yoshimoto G, Kato K, Takenaka K, Iwasaki H, Mizuno S, et al. The ordered acquisition of Class II and Class I mutations directs formation of human t(8;21) acute myelogenous leukemia stem cell. Exp Hematol. 2014.

Kobayashi R, Mitsui T, Fujita N, Osumi T, Aoki T, Aoki K, Suzuki R, Fukuda T, Miyamoto T, Kato K, et al. Outcome differences between children and adolescents and young adults with non-Hodgkin lymphoma following stem cell transplantation. Int J Hematol. 2016.

Sakurai M, Mori T, Kato K, Kanaya M, Mizuno S, Shiratori S, Wakayama T, Uchida N, Kobayashi H, Kubo K, et al. Outcome of allogeneic hematopoietic stem cell transplantation for follicular lymphoma relapsing after autologous transplantation: analysis of the Japan Society for Hematopoietic Cell Transplantation. Bone Marrow Transplant. 2021.

Yoshimitsu M, Fuji S, Utsunomiya A, Nakano N, Ito A, Ito Y, Miyamoto T, Suehiro Y, Kawakita T, Moriuchi Y, et al. Outcomes of allogeneic hematopoietic stem cell transplantation for ATL with HTLV-1 antibody positive donors: Allo-HCT for ATL from HTLV-1 antibody positive donors. Biol Blood Marrow Transplant. 2019.

P

Kawashima N, Iida M, Suzuki R, Fukuda T, Atsuta Y, Hashii Y, Inoue M, Kobayashi M, Yabe H, Okada K, et al. Prophylaxis and treatment with mycophenolate mofetil in children with graft-versus-host disease undergoing allogeneic hematopoietic stem cell transplantation: a nationwide survey in Japan. Int J Hematol. 2019.

R

Muramatsu H, Sakaguchi H, Taga T, Tabuchi K, Adachi S, Inoue M, Kitoh T, Suminoe A, Yabe H, Azuma E, et al. Reduced intensity conditioning in allogeneic stem cell transplantation for AML with Down syndrome. Pediatr Blood Cancer. 2013.

Nakaike T, Kato K, Oku S, Hayashi M, Kikushige Y, Kuroiwa M, Takenaka K, Iwasaki H, Miyamoto T, Teshima T, et al. Reduced-intensity conditioning followed by cord blood transplantation in a patient with refractory folliculotropic mycosis fungoides. Int J Hematol. 2013.

Pages